Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MPLT

MapLight Therapeutics Inc

Feb 13 • 04:00PM ET

17.22

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO SCHA IWO IWN IWC SCHB VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	61.40%	Shs Outstand	45.37M	Perf Week	1.41%
Market Cap	781.32M	Forward P/E	-	EPS next Y	-	Insider Trans	29.58%	Shs Float	17.51M	Perf Month	-8.21%
Enterprise Value	1.07B	PEG	-	EPS next Q	-0.99	Inst Own	10.08%	Short Float	7.26%	Perf Quarter	19.09%
Income	-	P/S	-	EPS this Y	-	Inst Trans	25.81%	Short Ratio	4.74	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.27M	Perf YTD	-1.96%
Book/sh	-6.04	P/C	3.44	EPS next 5Y	-	ROE	-	52W High	21.55 -20.09%	Perf Year	-
Cash/sh	5.01	P/FCF	-	EPS past 3/5Y	-60.77% -	ROIC	-	52W Low	12.24 40.69%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.63% 8.52%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.22	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.22	EPS Q/Q	-41.88%	SMA20	-2.16%	Beta	-	Target Price	31.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-5.22%	Rel Volume	1.18	Prev Close	17.22
Employees	-	LT Debt/Eq	0.02	Earnings	Dec 04 BMO	SMA200	0.76%	Avg Volume	268.04K	Price	17.22
IPO	Oct 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-2055.36% -	Trades		Volume	315,396	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-25	Initiated	Stifel	Buy	$28
Nov-21-25	Initiated	Morgan Stanley	Overweight	$34
Nov-21-25	Initiated	Leerink Partners	Outperform	$30
Nov-21-25	Initiated	Jefferies	Buy	$32

Jan-09-26 07:00AM	MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 (GlobeNewswire)
Jan-05-26 07:00AM	MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis (GlobeNewswire)
Dec-16-25 07:00AM	SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies (GlobeNewswire)
Dec-04-25 07:00AM	MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress (GlobeNewswire) +8.39%
Nov-07-25 07:26PM	MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors (Barrons.com)
09:06AM	Loading…
Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERT MALENKA	Director	Feb 13 '26	Proposed Sale	18.21	12,116	220,686		Feb 13 04:08 PM
Garnett Timothy John	Director	Feb 10 '26	Buy	17.89	14,124	252,678	14,124	Feb 12 05:45 PM
Malenka Robert C.	Director	Feb 10 '26	Sale	18.12	6,622	119,991	351,611	Feb 12 05:45 PM
Malenka Robert C.	Director	Feb 11 '26	Sale	18.00	241	4,338	351,370	Feb 12 05:45 PM
ROBERT MALENKA	Director	Feb 11 '26	Proposed Sale	18.00	241	4,338		Feb 11 04:13 PM
ROBERT MALENKA	Director	Feb 10 '26	Proposed Sale	18.12	6,622	119,963		Feb 10 04:22 PM
Malenka Robert C.	Director	Feb 02 '26	Sale	18.02	7,039	126,843	358,234	Feb 04 09:15 PM
Malenka Robert C.	Director	Feb 03 '26	Sale	18.00	1	18	358,233	Feb 04 09:15 PM
ROBERT MALENKA	Director	Feb 03 '26	Proposed Sale	18.00	1	18		Feb 03 04:15 PM
ROBERT MALENKA	Director	Feb 02 '26	Proposed Sale	18.02	7,039	126,835		Feb 02 04:37 PM
Malenka Robert C.	Director	Jan 29 '26	Sale	18.55	21,262	394,410	371,885	Jan 30 08:50 PM
Malenka Robert C.	Director	Jan 28 '26	Sale	18.65	6,524	121,704	393,147	Jan 30 08:50 PM
Malenka Robert C.	Director	Jan 30 '26	Sale	18.11	6,612	119,743	365,273	Jan 30 08:50 PM
ROBERT MALENKA	Director	Jan 30 '26	Proposed Sale	18.11	6,612	119,737		Jan 30 04:17 PM
ROBERT MALENKA	Director	Jan 29 '26	Proposed Sale	18.55	21,262	394,470		Jan 29 04:06 PM
ROBERT MALENKA	Director	Jan 28 '26	Proposed Sale	18.65	6,524	121,690		Jan 28 04:20 PM
Novo Holdings A/S	10% Owner	Oct 28 '25	Buy	17.00	952,941	16,199,997	3,686,622	Oct 30 04:31 PM
Catalyst4, Inc.	10% Owner	Oct 28 '25	Buy	17.00	5,441,176	92,499,992	19,697,464	Oct 29 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MPLT

MapLight Therapeutics Inc

Upgrade your FINVIZ experience